ArticleObesity surgery2026
MASLD Cluster Derived Outcomes after Metabolic-Bariatric Surgery: a Retrospective Single-Center Analysis.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease and is strongly associated with obesity. A novel approach of categorizing subtypes of MASLD has been proposed recently. Intent of this study was to investigate the influence of these clusters on weight loss and diabetes outcomes of metabolic-bariatric surgery (MBS). MATERIAL AND
methodsWe retrospectively analysed all patients undergone primary Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) between 2015 and 2025 in a german tertiary obsesty center. We performed the cluster differentiation proposed by Raverdy et al. along with a correlation of histolophathologic findings from liver biopsies collected during surgery and evaluated weight loss and diabetes remission at 12, 24 and 60 months after surgery.
resultsOverall, 588 out of 850 patients met the inclusion criteria for sufficient clustering of whom 49 were assigned to the cardiometabolic, 52 to the liver specific and 487 to the control cluster. Baseline characteristics differed regarding age, HbA1c, and type 2 diabetes (T2DM) (HbA1c: 8.4 in the cardiometabolic vs 6.2 liver specific; p < .001) between clusters. Liver fibrosis was found in 65% of the cardiometabolic, 41,4% in the liver specific cluster and 16.4% in the control cluster (p < .001). Postoperative complications did not differ between clusters. Total body weight loss (%TBWL) at 12, 24, 36 and 48 months was 22.1%, 19.7%, 17.9% and 18.7% in the cardiometabolic cluster vs. 29.5%, 29.9%, 29.3% and 25.2% in the liver specific cluster (p < .001). Secondary worsening of T2DM occurred in 36% at 24 months 37.5% at 60 months in the cardiometabolic cluster but in 0% in the liver specific (both p < .001).
conclusionPreoperative data-driven clustering for MASLD identifies distinct types of MASLD in MBS candidates, correlating with histological results. Cluster subtypes are associated with weight loss and diabetes outcomes with inferior outcomes for the cariometabolic cluster. These findings may have an impact on the risk-benefit ratio and on expectation management of MBS. KEY POINTS: Data-driven MASLD Clustering is reproducible in MBS candidates and correlates with histological findings. Cluster subtypes are associated with weight loss and diabetes outcomes after MBS. Patients assigned to cardiometabolic cluster show inferior weigth loss and diabetes outcomes. Clustering may impact individual treatment planning, expectation management, and targeted follow-up strategies.
Indexed as
Identifiers
42945022What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.